A specific subset of men with a specific genetic variation respond to non-steroidal CYP17A1 inhibition

Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer that was less responsive to treatment with androgen deprivation therapy (ADT). … READ MORE …

Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …